167 related articles for article (PubMed ID: 8606069)
1. Delineation by use of specific monoclonal antibodies of the T-cell receptor and major histocompatibility complex interaction sites on the superantigen toxic shock syndrome toxin 1.
Shimonkevitz R; Boen E; Malmstrom S; Brown E; Hurley JM; Kotzin BL; Matsumura M
Infect Immun; 1996 Apr; 64(4):1133-9. PubMed ID: 8606069
[TBL] [Abstract][Full Text] [Related]
2. The alpha 1 domain of the HLA-DR molecule is essential for high-affinity binding of the toxic shock syndrome toxin-1.
Karp DR; Teletski CL; Scholl P; Geha R; Long EO
Nature; 1990 Aug; 346(6283):474-6. PubMed ID: 2377209
[TBL] [Abstract][Full Text] [Related]
3. Human scFvs That Counteract Bioactivities of Staphylococcus aureus TSST-1.
Rukkawattanakul T; Sookrung N; Seesuay W; Onlamoon N; Diraphat P; Chaicumpa W; Indrawattana N
Toxins (Basel); 2017 Feb; 9(2):. PubMed ID: 28218671
[TBL] [Abstract][Full Text] [Related]
4. Receptors for toxic shock syndrome toxin-1 and staphylococcal enterotoxin A on human blood monocytes.
See RH; Krystal G; Chow AW
Can J Microbiol; 1992 Sep; 38(9):937-44. PubMed ID: 1281444
[TBL] [Abstract][Full Text] [Related]
5. The staphylococcal toxic shock syndrome toxin 1 triggers B cell proliferation and differentiation via major histocompatibility complex-unrestricted cognate T/B cell interaction.
Mourad W; Scholl P; Diaz A; Geha R; Chatila T
J Exp Med; 1989 Dec; 170(6):2011-22. PubMed ID: 2584933
[TBL] [Abstract][Full Text] [Related]
6. Toxic shock syndrome toxin 1 binds to major histocompatibility complex class II molecules.
Scholl P; Diez A; Mourad W; Parsonnet J; Geha RS; Chatila T
Proc Natl Acad Sci U S A; 1989 Jun; 86(11):4210-4. PubMed ID: 2542966
[TBL] [Abstract][Full Text] [Related]
7. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1.
von Bonin A; Ehrlich S; Malcherek G; Fleischer B
Eur J Immunol; 1995 Oct; 25(10):2894-8. PubMed ID: 7589089
[TBL] [Abstract][Full Text] [Related]
8. Binding of toxic shock syndrome toxin-1 to murine major histocompatibility complex class II molecules.
Scholl PR; Sekaly RP; Diez A; Glimcher LH; Geha RS
Eur J Immunol; 1990 Sep; 20(9):1911-6. PubMed ID: 2209697
[TBL] [Abstract][Full Text] [Related]
9. Identification of HLA-DR alpha chain residues critical for binding of the toxic shock syndrome toxin superantigen.
Panina-Bordignon P; Fu XT; Lanzavecchia A; Karr RW
J Exp Med; 1992 Dec; 176(6):1779-84. PubMed ID: 1460432
[TBL] [Abstract][Full Text] [Related]
10. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality.
Kum WW; Laupland KB; Chow AW
Can J Microbiol; 2000 Feb; 46(2):171-9. PubMed ID: 10721486
[TBL] [Abstract][Full Text] [Related]
11. Immune response to staphylococcal superantigens.
Krakauer T
Immunol Res; 1999; 20(2):163-73. PubMed ID: 10580640
[TBL] [Abstract][Full Text] [Related]
12. Dissection of the function of HLA class II and costimulation in B cell-mediated and toxic shock syndrome toxin-1-induced T cell proliferation.
Dennig D; O'Reilly RJ
J Immunol; 1993 Jun; 150(12):5231-40. PubMed ID: 7685791
[TBL] [Abstract][Full Text] [Related]
13. Staphylococcal enterotoxin B and toxic shock syndrome toxin-1 bind to distinct sites on HLA-DR and HLA-DQ molecules.
Scholl PR; Diez A; Geha RS
J Immunol; 1989 Oct; 143(8):2583-8. PubMed ID: 2551962
[TBL] [Abstract][Full Text] [Related]
14. Relative activities of distinct isotypes of murine and human major histocompatibility complex class II molecules in binding toxic shock syndrome toxin 1 and determination of CD antigens expressed on T cells generated upon stimulation by the toxin.
Uchiyama T; Saito S; Inoko H; Yan XJ; Imanishi K; Araake M; Igarashi H
Infect Immun; 1990 Dec; 58(12):3877-82. PubMed ID: 2123824
[TBL] [Abstract][Full Text] [Related]
15. Activation of murine T cells by toxic shock syndrome toxin-1. The toxin-binding structures expressed on murine accessory cells are MHC class II molecules.
Uchiyama T; Tadakuma T; Imanishi K; Araake M; Saito S; Yan XJ; Fujikawa H; Igarashi H; Yamaura N
J Immunol; 1989 Nov; 143(10):3175-82. PubMed ID: 2509554
[TBL] [Abstract][Full Text] [Related]
16. Identification of class II major histocompatibility complex and T cell receptor binding sites in the superantigen toxic shock syndrome toxin 1.
Hurley JM; Shimonkevitz R; Hanagan A; Enney K; Boen E; Malmstrom S; Kotzin BL; Matsumura M
J Exp Med; 1995 Jun; 181(6):2229-35. PubMed ID: 7760008
[TBL] [Abstract][Full Text] [Related]
17. Binding sites for bacterial and endogenous retroviral superantigens can be dissociated on major histocompatibility complex class II molecules.
Thibodeau J; Labrecque N; Denis F; Huber BT; Sékaly RP
J Exp Med; 1994 Mar; 179(3):1029-34. PubMed ID: 8113671
[TBL] [Abstract][Full Text] [Related]
18. Activation of human vascular endothelial cells by IFN-gamma: acquisition of HLA class II expression, TSST-1-binding activity and accessory activity in T cell activation by the toxin.
Araake M; Uchiyama T; Imanishi K; Yan XJ
Int Arch Allergy Appl Immunol; 1991; 96(1):55-61. PubMed ID: 1752697
[TBL] [Abstract][Full Text] [Related]
19. Identification of MHC class II-associated peptides that promote the presentation of toxic shock syndrome toxin-1 to T cells.
Hogan RJ; VanBeek J; Broussard DR; Surman SL; Woodland DL
J Immunol; 2001 Jun; 166(11):6514-22. PubMed ID: 11359802
[TBL] [Abstract][Full Text] [Related]
20. A toxic shock syndrome toxin-1 peptide that shows homology to amino acids 180-193 of mycobacterial heat shock protein 65 is presented as conventional antigen.
Ramesh N; Parronchi P; Ahern D; Romagnani S; Geha R
Immunol Invest; 1994 Nov; 23(6-7):381-91. PubMed ID: 7851957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
